Jump to:
Oxford Cannabinoid Technologies Holdings PLC Fundamentals
Company Name | Oxford Cannabinoid Technologies Holdings PLC | Last Updated | 2024-05-10 |
---|
Industry | Biotechnology | Sector | Healthcare |
---|
Shares in Issue | 1.088 bn | Market Cap | £1.63 m |
---|
PE Ratio | 0.00 | Dividend per Share | 0 |
---|
Dividend Yield | 0 | Dividend Cover | 0 |
---|
EPS | -£0.01 | EPS Growth (%) | 0 |
---|
PEG | 0 | DPS Growth (%) | 0 |
---|
Debt Ratio | 0 | Debt Equity Ratio | 0 |
---|
Asset Equity Ratio | 1.4308 | Cash Equity Ratio | 0.5815 |
---|
Quick Ratio | 3.3214 | Current Ratio | 3.32 |
---|
Price To Book Value | 0.8372 | ROCE | 0 |
---|
Oxford Cannabinoid Technologies Holdings PLC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Oxford Cannabinoid Technologies Holdings PLC Company Financials
Assets | 2023 | 2022 | 2021 |
---|
Tangible Assets | 0 | 0 | £57,391.00 |
Intangible Assets | £7,272.00 | £46,080.00 | £101,657.00 |
Investments | 0 | 0 | 0 |
Total Fixed Assets | £7,272.00 | £46,080.00 | £159,048.00 |
Stocks | 0 | 0 | 0 |
Debtors | £301,151.00 | £1.51 m | £92,321.00 |
Cash & Equivalents | £2.30 m | £9.17 m | £14.63 m |
Other Assets | 0 | 0 | 0 |
Total Assets | £4.50 m | £11.82 m | £15.21 m |
Liabilities | 2023 | 2022 | 2021 |
---|
Creditors within 1 year | £583,920.00 | £2.03 m | £951,135.00 |
Creditors after 1 year | 0 | 0 | £46,864.00 |
Other Liabilities | 0 | 0 | 0 |
Total Liabilities | £583,920.00 | £2.03 m | £997,999.00 |
Net assets | £3.91 m | £9.79 m | £14.21 m |
Equity | 2023 | 2022 | 2021 |
---|
Called up share capital | £9.60 m | £9.60 m | £9.60 m |
Share Premium | £11.88 m | £11.88 m | £11.88 m |
Profit / Loss | -£7.03 m | -£5.50 m | -£3.37 m |
Other Equity | £3.91 m | £9.79 m | £14.21 m |
Preference & Minorities | 0 | 0 | 0 |
Total Capital Employed | £3.91 m | £9.79 m | £14.21 m |
Ratios | 2023 | 2022 | 2021 |
---|
Debt Ratio | 0 | £0.00 | 0 |
Debt-to-Equity | 0 | £0.00 | 0 |
Assets / Equity | 1.4308 | 1.4308 | 1.4308 |
Cash / Equity | 0.5815 | 0.5815 | 0.5815 |
EPS | -£0.01 | £-0.00 | £-0.00 |
Cash Flow | 2023 | 2022 | 2021 |
---|
Cash from operating activities | -£6.87 m | -£5.37 m | -£1.78 m |
Cashflow before financing | -£6.87 m | -£5.47 m | £14.27 m |
Increase in Cash | -£6.87 m | -£5.47 m | £14.32 m |
Income | 2023 | 2022 | 2021 |
---|
Turnover | 0 | 0 | 0 |
Cost of sales | £4.30 m | £2.89 m | £445,400.00 |
Gross Profit | -£4.30 m | -£2.89 m | -£445,400.00 |
Operating Profit | -£7.04 m | -£5.50 m | -£3.35 m |
Pre-Tax profit | -£7.03 m | -£5.50 m | -£3.37 m |
Oxford Cannabinoid Technologies Holdings PLC Company Background
Sector | Healthcare |
---|
Activities | Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines. |
---|
Latest Interim Date | 30 Jan 2024 |
---|
Latest Fiscal Year End Date | 31 Aug 2023 |
---|
Oxford Cannabinoid Technologies Holdings PLC Directors
Appointed | Name | Position |
---|
2024-02-26 | Ms. Julie Patricia Pomeroy | Non-Executive Director,Chairman |
2023-10-20 | Mr. Indraneil Mahapatra | Non-Executive Director |
2024-02-26 | Ms. Clarissa Ann Sowemimo-Coker | Executive Director,Chief Executive Officer |
2023-09-06 | Ms. Karen Lowe | Executive Director,Finance Director |
2023-01-24 | Mr. Gavin Hilary Sathianathan | Non-Executive Director |
2024-03-29 | Mr. Bishrut Mukherjee | Non-Executive Director |
2022-08-04 | Mr. Charanjit Cheryl Dhillon | Non-Executive Director |
Oxford Cannabinoid Technologies Holdings PLC Contact Details
Oxford Cannabinoid Technologies Holdings PLC Advisors